Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | GALK1 | P51570 | 2/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Theaflavin Digallate SCHEMBL12240725 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPTRECQLKMT2A | |
| Theaflavin Digallate SCHEMBL17131968 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPTRECQLKMT2A | |
| Theaflavin Digallate SCHEMBL29392662 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPTRECQLKMT2A | |
| Theaflavin Digallate SCHEMBL31695388 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPTRECQLKMT2A | |
| Theaflavin Digallate SCHEMBL13287244 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPTRECQLKMT2A | |
| Theaflavin Digallate SCHEMBL12672295 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPTRECQLKMT2A | |
| Theaflavin Digallate SCHEMBL29364383 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPTRECQLKMT2A | |
| Theaflavin Digallate SCHEMBL29463978 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPTRECQLKMT2A | |
| Theaflavin Digallate SCHEMBL12658741 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPTRECQLKMT2A | |
| SCHEMBL17206814 | 0.99 | KDM4E (0.98) | KDM4EMEN1MAPTRECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9101656-B2 | Use of tea-derived, theaflavin enriched extract to increase exercise performance and reduce exercise recovery time | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-08-11 | — | — | US | disclosed |
| US-8563047-B2 | Use of tea-derived, theaflavin enriched extract to increase exercise performance and reduce exercise recovery time | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-10-22 | — | — | US | disclosed |
| US-20100015254-A1 | Use of tea-derived, theaflavin enriched extract to increase exercise performance and reduce exercise recovery time | STATE UNIVERSITY OF NEW JERSEY RUTGERS, THE | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015254-A1 | Use of tea-derived, theaflavin enriched extract to increase exercise performance and reduce exercise recovery time | TES, TEAD3, CPT1B | KDM4E 2800/4885MEN1 4645/4885MAPT 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.